Case at a glance: The Supreme Court has quashed the blacklisting and debarment of a medicine supplier to Madhya Pradesh government hospitals whose batches of Vitamin C and Ethambutol tablets were declared not of standard quality. The tender required a second sample to be tested at another laboratory, which was never done. With all batches now expired and the retest opportunity lost through the State’s delay, the Court held the punitive action could not stand.
The appellant supplied Ascorbic Acid 500 mg and Ethambutol Hydrochloride 400 mg tablets to district hospitals under tenders of the Madhya Pradesh Public Health Services Corporation (MPPHSCL). Four batches were reported Not of Standard Quality. After a show-cause notice of 23 September 2024, the Managing Director on 30 September 2024 debarred the firm for two years for Ethambutol and blacklisted it for three years for Ascorbic Acid, with recovery of Rs 3,47,375 and Rs 6,77,219; a representation was rejected on 1 October 2024.
The Madhya Pradesh High Court found that Clause 6 of Annexure IX, requiring a second sample to be tested at another laboratory, had not been complied with, but instead of quashing the orders it directed fresh samples to be sent to the Central Government Laboratory within 15 days. No retest took place, and review petitions were dismissed on 12 February 2026.
The Key Question Before the Court
Can blacklisting and debarment based on failed drug samples survive when the mandatory retest under the tender was never done and the batches have since expired?
Lost Retest, Lost Case
Writing for the Bench, Justice Mehta noted that the respondents could not dispute that Clause 6 had not been followed, and that “the blacklisting orders were passed without complying with the mandatory requirement under Clause 6”. Having found this, the High Court was not justified in making the fate of the orders depend on a retest. That retest never happened even by the review stage, the rate contracts had expired, and all four batches had expired, so a retest ‘has lost its purpose’.
Applying by analogy Medipol Pharmaceutical India v. PGIMER, (2020) 08 SC CK 0051, which drew on Medicamen Biotech v. Rubina Bose, (2008) 03 SC CK 0133 and Laborate Pharmaceuticals v. State of Tamil Nadu, (2017) 02 SC CK 0003, the Court held that where delay attributable to the State deprives the supplier of an effective retest, adverse action cannot be sustained. Though those were criminal cases under the Drugs and Cosmetics Act, blacklisting carries serious civil consequences, and the lapse “renders the orders of blacklisting and debarment unsustainable in law.”
What the Court Actually Held
- The blacklisting and debarment orders of 30 September 2024 and 1 October 2024 were quashed.
- The High Court orders of 27 October 2025 and 12 February 2026 were set aside to the extent they declined to quash and made the orders contingent on retesting.
- Delay attributable to the State that defeats an effective retest invalidates the adverse action.
- The appeals were allowed.
Why This Judgment Matters
- It makes tender retest clauses enforceable conditions, not formalities.
- It extends the Medipol principle from prosecutions to administrative blacklisting.
- It warns courts against keeping punitive orders alive pending a retest that may never happen.
What Should Advocates Take Away From the Judgment?
For Suppliers
- Invoke retest clauses and Section 25 of the Drugs and Cosmetics Act promptly and in writing.
- Where the State delays until the shelf life expires, rely on Medipol and this judgment.
For Procurement Agencies
- Send the second sample to the designated laboratory before blacklisting.
- Act within the shelf life of the batch; delay can defeat the action entirely.
Key Takeaways
- Clause 6 retest was mandatory.
- Blacklisting without it was unsustainable.
- State delay that defeats a retest invalidates adverse action.
- Courts should not keep such orders alive pending retest.
Frequently Asked Questions
Because the mandatory second-sample test under Clause 6 was never done, and the State’s delay meant an effective retest was no longer possible.
No. It did not decide quality; it held the procedure was not followed and the retest opportunity was lost.
The Court applied its principle by analogy to blacklisting, given its serious civil consequences.
Conclusion
The judgment insists that a State that writes a retest safeguard into its tender must honour it before imposing the severe penalty of blacklisting.
Practical takeaway: A blacklisting based on failed drug samples is vulnerable if the contractual or statutory retest was not done in time; suppliers should demand it promptly and record the demand.
For more judgments, legal opinions and case analysis, visit courtkutchehry.com
Visit CourtKutchehry →